Radiomic Analysis of Magnetic Resonance Fingerprinting in Adult Brain Tumors
Overview
Nuclear Medicine
Radiology
Authors
Affiliations
Purpose: This is a radiomics study investigating the ability of texture analysis of MRF maps to improve differentiation between intra-axial adult brain tumors and to predict survival in the glioblastoma cohort.
Methods: Magnetic resonance fingerprinting (MRF) acquisition was performed on 31 patients across 3 groups: 17 glioblastomas, 6 low-grade gliomas, and 8 metastases. Using regions of interest for the solid tumor and peritumoral white matter on T1 and T2 maps, second-order texture features were calculated from gray-level co-occurrence matrices and gray-level run length matrices. Selected features were compared across the three tumor groups using Wilcoxon rank-sum test. Receiver operating characteristic curve analysis was performed for each feature. Kaplan-Meier method was used for survival analysis with log rank tests.
Results: Low-grade gliomas and glioblastomas had significantly higher run percentage, run entropy, and information measure of correlation 1 on T1 than metastases (p < 0.017). The best separation of all three tumor types was seen utilizing inverse difference normalized and homogeneity values for peritumoral white matter in both T1 and T2 maps (p < 0.017). In solid tumor T2 maps, lower values in entropy and higher values of maximum probability and high-gray run emphasis were associated with longer survival in glioblastoma patients (p < 0.05). Several texture features were associated with longer survival in glioblastoma patients on peritumoral white matter T1 maps (p < 0.05).
Conclusion: Texture analysis of MRF-derived maps can improve our ability to differentiate common adult brain tumors by characterizing tumor heterogeneity, and may have a role in predicting outcomes in patients with glioblastoma.
Orzan F, Iancu S, Diosan L, Balint Z Front Neurosci. 2025; 18:1457420.
PMID: 39906910 PMC: 11790655. DOI: 10.3389/fnins.2024.1457420.
Song D, Fan G, Chang M Cancers (Basel). 2025; 17(1.
PMID: 39796702 PMC: 11719598. DOI: 10.3390/cancers17010074.
Cui D, Liu X, Larson P, Xu D Magn Reson Med. 2024; 93(4):1751-1760.
PMID: 39567357 PMC: 11842023. DOI: 10.1002/mrm.30381.
Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies.
Nguyen T, Greene L, Mnatsakanyan H, Badr C Biomedicines. 2024; 12(6).
PMID: 38927583 PMC: 11202201. DOI: 10.3390/biomedicines12061376.
Monga A, Singh D, De Moura H, Zhang X, Zibetti M, Regatte R Bioengineering (Basel). 2024; 11(3).
PMID: 38534511 PMC: 10968015. DOI: 10.3390/bioengineering11030236.